Astellas Pharma to buy Audentes Therapeutics for $3bn

Under the deal, Astellas US Holding wholly-owned subsidiary Asilomar Acquisition will acquire Audentes by paying $60 per share in cash. Audentes chairman and CEO Matthew Patterson said: “With

The post Astellas Pharma to buy Audentes Therapeutics for $3bn appeared first on Pharmaceutical Business review.

Merck’s Keytruda gets FDA priority review for high-risk NMIBC

The new supplemental Biologics License Application (sBLA) for Keytruda, which has been accepted by the FDA is for the treatment of patients having Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle

The post Merck’s Keytruda gets FDA priority review for high-risk NMIBC appeared first on Pharmaceutical Business review.

LUNAC Therapeutics-led project awarded £3.14m under Innovate UK Biomedical Catalyst Programme, to develop next-generation anticoagulant

The funding will be used to develop an innovative anticoagulant treatment with minimal bleeding risk, to better meet patient need. The 18-month preclinical drug discovery project brings together

The post LUNAC Therapeutics-led project awarded £3.14m under Innovate UK Biomedical Catalyst Programme, to develop next-generation anticoagulant appeared first on Pharmaceutical Business review.

Sensorion’s Seliforant to treat AUV fails to meet primary endpoint in phase 2b trial

SENS-111 is an orally available small molecule histamine type 4 receptor antagonist, which delivers an inhibitory effect on vestibular neuron activity. According to the company, the SENS-111 was

The post Sensorion’s Seliforant to treat AUV fails to meet primary endpoint in phase 2b trial appeared first on Pharmaceutical Business review.